HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Avoparcin

HCID 16132294
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
37332-99-3
Standard SMILES
CN[C@@H](C(=O)N[C@H]1C(=O)N[C@@H](c2ccc(O)cc2)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@@H](N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)C2O[C@H]2C[C@@H](N)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2)[C@H]1O)c1ccc(O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)cc1
InChIKey
XQKGPVCSSWFILW-BQNCTUMNSA-N
Molecular formula
C83H92ClN9O31
Average molar mass
1,747.1 g/mol
Monoisotopic mass
1,745.5587749

Overview

Avoparcin alpha is an oligopeptide.

Names & identifiers

Preferred name
Avoparcin
IUPAC
(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4R,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-48-[(2S,4S,5S,6R)-3-[(2R,4R,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-chloro-18,32,35,37-tetrahydroxy-22-(4-hydroxyphenyl)-19-[[(2R)-2-(methylamino)-2-[4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphenyl]acetyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14(47),15,17(46),29(45),30,32,34(39),35,37,49-pentadecaene-40-carboxylic acid
English name
Avoparcin
Molecular formula
C89H102ClN9O36
Molecular weight
1909.26

Names & synonyms

AvoparcinAvoparcinaAvoparcineAvoparcinumAvotanCompound 254Avotan 5037332-99-3LL-AV290AV-290WJ13O9MNTICL 81,588
Show more names
AvapaavomycinAvoparicinAvoparcin (Mixture of alfa- and beta-Isomers)
C-254CL 81,587RefChem:560424DTXSID901053265CL-81587253-466-4(1S,2R,18R,19R,22S,25R,28R,40S)-2-((2R,4R,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-48-((2S,4S,5S,6R)-3-((2R,4R,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy-5-chloro-18,20,23,26,32,35,37,42,44-nonahydroxy-19-(((2R)-1-hydroxy-2-(methylamino)-2-(4-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphenyl)ethylidene)amino)-22-(4-hydroxyphenyl)-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo(26.14.2.23,6.214,17.18,12.129,33.010,25.034,39)pentaconta-3,5,8,10,12(48),14(47),15,17(46),20,23,26,29(45),30,32,34(39),35,37,41,43,49-icosaene-40-carboxylic acidUNII-WJ13O9MNTI

Database identifiers

CAS

Properties

Computed structural propertiesFilling in

XLogP
-3
Topological polar surface area
631 Ų
Hydrogen bond donors
23
Hydrogen bond acceptors
34
Rotatable bonds
15
Heavy atoms
124
Formal charge
0
Complexity
3,620

Experimental & physicochemical properties

Chemical ClassesOther Uses -> Animal Feed Additives
pHMaximum stability of aqueous solutions is at pH 4-8
Color/FormWhite, amorphous solid
Solubility · 2 items

Soluble in water

Soluble in N,N-dimethylformamide, dimethyl sulfoxide. Moderately soluble in methanol.

Melting PointNo definitive melting point
Optical Rotation · 2 items

Specific optical rotation = -96 deg at 25 °C/D (error within 2 deg) (c = 0.62 in 0.1N HCl). UV max (0.1N HCL): 280 nm. The absorbance of a solution containing one gram per 100 mL contained in a cell having an absorption path of one cm = 42.0 /alpha-Avoparcin/

Specific optical rotation = -102 deg at 25 °C/D (error within 2 deg) (c = 0.65 in 0.1N HCl). UV max (0.1N HCl): 280 nm. The absorbance of a solution containing one gram per 100 ml contained in a cell having an absorption path of one cm = 44.0 /beta-Avoparcin/

Physical DescriptionWhite solid; Hygroscopic; [Merck Index]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Regulatory InformationAvoparcin: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - Avoparcin: Environment tier I assessment

Safety & protection

Disposal Methods · 1 item

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Toxicology

Toxicity Summary · 1 item

IDENTIFICATION AND USE: Avoparcin is an antimicrobial antibiotic that has been widely used in feed for poultry, pigs, calves, cattle for fattening and lambs, due to its positive effects on animal growth. At the time since vancomycin was not widely used, there was little reason to be concerned about resistance problems in humans. Things changed, however, when vancomycin became critical in human medicine for treatment of methicillin-resistant Staphylococcus aureus (MRSA) and other serious infections. Resistance to vancomycin, especially among enterococci (VRE) became an important public health problem in many countries. Researchers identified VRE in animals exposed to avoparcin, where they were not found in animals in countries where avoparcin was not used as a growth promoter. Furthermore, the prevalence of VRE among non-hospitalized people in the community was much higher in countries that used avoparcin. There is evidence that VRE in food animals may have been a reservoir for resistance in humans, perhaps through exchange of genetic material between animal and human strains, or through transient colonization of the human gut by animal strains. Avoparcin was never approved for use in the United States and its use has been banned in the European Union since 1997.HUMAN EXPOSURE AND TOXICITY: A case of contact dermatitis in a 50 year old woman resulted from exposure to avoparcin. ANIMAL STUDIES: Studies have shown an association between the use of the glycopeptide antibiotic avoparcin as a growth promoter and the occurrence of Enterococcus faecium (VREF) with high-level resistance to vancomycin on poultry and pig farms. The investigations were conducted as retrospective cohort studies, where groups of farms exposed or not exposed to avoparcin were compared. In poultry, the association between the use of avoparcin and the occurrence of VREF was confounded by the use of broad-spectrum antibiotics. In pigs, the association had a similar magnitude. The similar findings in the two studies provide evidence in favor of a causal association between the use of avoparcin and the occurrence of VREF on farms, and suggest that food animals constitute a potential reservoir of infection for VREF in humans.

Chemistry & industry

Uses & manufacturing

Uses · 6 items

Used as a veterinary antibiotic (glycopeptide produced by Streptomyces candidus) and growth promotant; [Merck Index]

Farming (Pesticides) [Category: Industry]

Anti-Bacterial Agents

MEDICATION (VET)

A glycopeptide antibiotic

Feed additive for food-producing species

Methods of Manufacturing · 2 items

Avoparcin is a glycopeptide antibiotic complex produced by Streptomyces candidus. It consists of a mixture of alpha- and beta-avoparacin (chlorine-substituted analogue).

Production: M. P. Kunstmann, J. N. Porter, USA patent 3338786 (1967 to American Cyanamid).

General Manufacturing Information · 2 items

Never licenced in the US

... In countries using avoparcin ... as a growth promoter, vancomycin-resistant enterococci (VRE) are commonly found in the commensal flora of food animals, on meat from these animals and in commensal flora of healthy humans despite very limited use of vancomycin in hospitals. ...

Applications

UsesAntibacterial.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
37332-99-3
PubChem CID
16132294
ChEBI
CHEBI:221101
EC Number
253-466-4
Other Experimental Properties · 2 items

Hygroscopic

The epimerization of avoparcin entities is discussed in some detail. The absolute stereochemistry of avoparcin is now known since the N-methyl terminal amino acid of the aglycone has been isolated & shown to exhibit negative optical rotation & hence has the R-configuration. The same amino acid has been isolated from an epimerized solution of avoparcin & found to have positive rotation & hence the S-configuration. A comparison is made of the CD curves of beta-avoparcin & epi-beta-avoparcin. Some discussion on the effect of protonation of the terminal N-methyl group on the antibacterial activity of avoparcin is included.

Physicochemical properties

EWG's Food Scores
1 · 1
FDA UNII
13 O9MNTI · WJ13O9MNTI
Hazardous Substances Data
37332 · 37332-99-3(Hazardous Substances Data)
Toxicity
50 in · LD50 in mice, rats, and chickens: >10000 mg/kg orally (Am. Cyanamid, company literature)
Natural Pollution SourcesAvoparcin is a glycopeptide produced by Streptomyces candidus(1).
Human Toxicity Excerpts · 3 items

/CASE REPORTS/ A case of contact dermatitis resulting from exposure to avoparcin was described. A 50 year old housewife with a 15 month history of erythema and pruritus on the skin under her corset was examined at a Spanish dermatology clinic. Previous patch testing had yielded positive reactions to nickel and cobalt. Treatment with topical corticosteroids and oral antihistamines at the time had produced little improvement. Examination revealed erythema and pruritus with slight scaling and well defined borders on the skin under her brassiere. Further patch testing confirmed her allergies to nickel and cobalt. Since she had mentioned helping her husband with farm work, she was also patch tested with samples of animal feed and their components. This produced positive reactions to avoparcin, a veterinary antibiotic, and to cobalt. An atomic absorption spectrophotometric analysis of her corset and brassiere detected 70 parts per million cobalt. Analysis of a new brassiere of the same brand and type did not detect cobalt. Wearing the new brassiere while not doing farm work caused no skin problems. The authors conclude that sensitization to cobalt alone does not appear to be the cause of the dermatitis of the patient. Avoparcin may be an additional important factor in her dermatitis.

/OTHER TOXICITY INFORMATION/ With the exception of flavomycin & olaquindox, the antibiotics currently used in European countries as feed additives exert a Gram-positive spectrum of activity. Of these, tylosin & virginiamycin are known for cross-resistance to macrolides, lincosamidines & streptogramines, & avoparcin is known for cross-resistance to vancomycin & teicoplanin. The use of avoparcin in animal husbandry creates a potential reservoir of transferable, vanA-mediated glycopeptide resistance in enterococci. A study in a rural area in Germany where vancomycin-resistant enterococci (VRE) were not isolated from infected humans but found in animal husbandry has shown that VRE are disseminated via meat products & are also found in fecal samples of non-hospitalized humans. VRE of different ecological origin from Germany (hospitals, sewage, food, animal husbandry) are polyclonal as evidenced by macrorestriction patterns & multilocus enzyme electrophoresis, suggesting a wide dissemination of the vanA gene cluster. These results confirm earlier observations on the spread of the sat genes, which confer resistance to a streptothricin antibiotic which has only been used in animal feeding. The resistance determinants were later also found in Escherichia coli from human infections & had spread in the absence of selective pressure.

/OTHER TOXICITY INFORMATION/ Avoparcin is a glycopeptide antimicrobial in the same family as vancomycin. It was approved for use in many European countries as a growth promoter. At the time since vancomycin was not widely used, there was little reason to be concerned about resistance problems in humans. Things changed, however, when vancomycin became critical in human medicine for treatment of methicillin-resistant Staphylococcus aureus (MRSA) and other serious infections. Resistance to vancomycin, especially among enterococci (VRE) became an important public health problem in many countries. Researchers identified VRE in food animals exposed to avoparcin, where they were not found in animals in countries where avoparcin was not used as a growth promoter. Furthermore, the prevalence of VRE among non-hospitalized people in the community was much higher in countries that used avoparcin. There is evidence that VRE in food animals may have been a reservoir for resistance in humans, perhaps through exchange of genetic material between animal and human strains, or through transient colonization of the human gut by animal strains.

Artificial Pollution Sources · 2 items

Avoparcin's production may result in its release to the environment through various waste streams; its use to increase feed conversion efficiency and promote growth in poultry, pigs, and cattle(1) may result in its direct release to the environment(SRC).

Avoparcin was never licenced in the US(1). It was banned from use in Sweden in 1986 (2), Norway in 1995(3) by the European Union between 1997 and 1999(4), and Taiwan in 2000(5).

Non-Human Toxicity Excerpts · 2 items

/OTHER TOXICITY INFORMATION/ We determined the association between the use of the glycopeptide antibiotic avoparcin as a growth promoter and the occurrence of Enterococcus faecium (VREF) with high-level resistance to vancomycin (MIC > or = 64 ug mL-1) on poultry and pig farms. The investigations were conducted as retrospective cohort studies, where groups of farms exposed or not exposed to avoparcin between September 1994 and April 1995 were compared. In poultry, the association between the use of avoparcin and the occurrence of VREF was confounded by the use of broad-spectrum antibiotics, and the adjusted relative risk was 2.9 (1.4-5.9). In pigs, the association had a similar magnitude with a non-adjusted relative risk of 3.3 (0.9-12.3). The similar findings in the two studies provide evidence in favor of a causal association between the use of avoparcin and the occurrence of VREF on farms, and suggest that food animals constitute a potential reservoir of infection for VREF in humans.

/OTHER TOXICITY INFORMATION/ An experiment was carried out with male broiler chicks to evaluate the combined effect of monensin (150 mg/kg) & the growth promoters (GPs) Zn bacitracin (BAC, 50 mg/kg), virginiamycin (VIR, 25 mg/kg) & avoparcin (AVO, 20 mg/kg) fed from 7 to 28 days of age on performance, utilization of dietary nutrients, yield of defeathered eviscerated carcases (DEC) & size of various organs. The effect of the GPs in the monensin-unsupplemented diets fed up to 49 d of age on performance & carcase was also determined. Monensin significantly (P < 0.05) depressed food intake, weight gain & food efficiency from 7 to 28 d of age. None of the GPs was able to counteract these effects. However, AVO slightly ameliorated them. AVO also significantly increased food intake & improved gain & food efficiency during 7 to 28, but not 28 to 49 or 7 to 49 d of age. VIR & BAC did not affect performance in either age period. Monensin did not affect the utilisation of dietary dry matter, fat or energy, but it significantly decreased nitrogen utilisation. AVO improved nitrogen & fat utilisation & increased dietary AME(n) content. AME(n) was also increased by VIR. The utilisation of these nutrients was not affected by the interactions between monensin & the GPs. Monensin did not affect yield of the DEC or the relative liver size at 31 d of age. It significantly increased the relative length of the small intestine (SI) & decreased its specific weight. AVO significantly increased yield at 31, but not at 53 d of age. BAC & VIR did not affect this variable. AVO & VIR, but not BAC, at both age periods reduced, at times significantly, the size, length & specific weight of the SI. Our conclusions: BAC, VIR & AVO do not counteract the toxic effect of monensin. The effect of GPs in improving performance decreases & even disappears with age, while their effect in reducing the size of the SI is still evident in 49 day old birds.

Antidote and Emergency Treatment · 5 items

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

Emergency and supportive measures. 1. Maintain an open airway and assist ventilation if necessary. 2. Treat coma, seizures, hypotension, anaphylaxis, and hemolysis if they occur. 3. replace fluid losses resulting from gastroenteritis with IV crystalloids. 4. Maintain steady urine flow with fluids to alleviate crystalluria from overdoses of sulfonamides, ampicillin, or amoxicillin. /Antibacterial agents/

For more Antidote and Emergency Treatment (Complete) data for AVOPARCIN (6 total), please visit the HSDB record page.

Safety data

Toxicity
LD50 in mice, rats, and chickens: >10000 mg/kg orally (Am. Cyanamid, company literature)
Hazardous Substances Data
37332-99-3(Hazardous Substances Data)